Most investors are still guessing when to buy. 📊 We built Cultivate to read market momentum in real time — leaning into hot names, pulling back when things turn. Result: 110% in one yr vs 19% S&P 500 (forward-tested). Not advice. #Cultivate#MomentumInvesting
MRNA down 23.5% today, giving back part of yesterday's record +177% spike after Wed's Phase 3 win for its mRNA cancer vaccine w/ Merck's Keytruda. Pullback = profit-taking, not a verdict on the science. Not financial advice. #MRNA#Moderna#Biotech
UUUU isn't just a uranium miner anymore — its White Mesa Mill now makes rare earths + vanadium, plus a $1.9B deal for magnet maker Vacuumschmelze. Our models see ~$23.50/share (+68%) in 12mo. Forecast, not guarantee. #UUUU#Uranium#RareEarths
MRNA up 178% today. Moderna+Merck's personalized mRNA cancer vaccine (w/ Keytruda) hit primary endpoints in Phase 3 melanoma trial — first personalized mRNA cancer therapy ever to clear Ph3. MRK +12%. Not advice. #MRNA
HIVE: More Than Just a Bitcoin Miner? ⚡ Mined 2,885 BTC this yr, hashrate 6.5→25.1 EH/s. Via BUZZ, converting GPUs to AI/HPC: $19.5M rev, +94% YoY. Planning 320MW AI Gigafactory (100k+ GPUs). Total rev $297.8M, +158%. Projected ~$11.50/shr, ~299% upside. Not advice. #HIVE#AI
CVNA -7.22% to $65.41 today — S&P's biggest mover. Concern: Guggenheim's Mark Walter may be forced to sell his ~4% CVNA stake amid a federal probe (unrelated to Carvana ops). Record quarter otherwise (+38% rev YoY). Not financial advice. #CVNA#Carvana
MP Materials: from rare earth miner to the only vertically integrated magnet producer in the US. DoD backing + $110/kg price floor, Apple magnet deal starting 2027. Our target: ~$100/shr (77% upside) in 12mo. Not financial advice. #MPMaterials#RareEarth
MSTR holds 843K+ BTC but its software arm is profitable too. We project ~$300/share (208% upside) in 12mo vs Street's ~$235. Not financial advice. #MSTR#Bitcoin
SNDK is up 8.91% today 📈 JPMorgan reinstated Overweight, $2,250 target, after Sandisk's Investor Day guidance + new 9th-gen flash tech w/ Kioxia. Up ~35% this week as AI storage demand reprices the stock. Not financial advice. #SNDK#Semiconductors
5 Stocks We're Watching This Week 👀
AI infra & data storage dominate the radar this week.
$NBIS +47.7% (Q2 rev +454%)
$SNDK +35.4%
$STX +19.8%
$WDC +17.2%
$CRWV +16.1% ($104B backlog)
Not financial advice.
#AIInfrastructure#StocksToWatch
Here's what we're holding (no $ amounts): 36 positions, 7 frontier-tech sectors. Space & Aerospace leads at 31%.
Top 5: BKSY (5.10%), RDW (4.32%), ONDS (4.15%), USAR (4.04%), INFQ (4.03%).
Snapshot, not advice. Not financial advice.
#PortfolioUpdate#StockMarket
SMCI up ~9% today. Q4 EPS beat: $1.62 vs $0.96 est. Rev $11.1B (light), but FY26 guide $65-72B + $60B+ backlog sent shares up ~8% after-hours.
One print, not confirmation. Not financial advice.
#SMCI#Earnings#AIStocks
VOYG isn't just "the ISS replacement" — Starlab's the catalyst, but Voyager's also a defense contractor + space infra business.
FY26 guide: $275-305M rev, $336M backlog.
Our model: ~$75/sh (12mo), ~75% upside vs Street's ~$45.
Not financial advice. #VOYG#Space
USAR: More than a mining company ⛏️
Full mine-to-magnet supply chain — Round Top deposit + Stillwater OK magnet plant. Merger w/ Texas Mineral Resources closed Aug 7.
Our model: ~$50/sh in 12mo (~184% upside).
Not financial advice.
#USAR#RareEarth
VRTX is up 5.61% today — here's why. 📈
Vertex's Phase 3 data for non-opioid pain candidate suzetrigine beat on safety + efficacy, and mgmt raised FY guidance on CF launches. Real derisking event, not just hype.
Not financial advice.
#VRTX#Biotech
TTD is down 22% today — here's why. 📉 Q2 revenue and EPS both missed, and Q3 guidance came in ~19% below consensus alongside a CFO/CMO/commercial-chief shakeup. 4+ analysts cut ratings within hours. Not financial advice.
$TTD
#stocks
ACHR: more than just an air taxi company. ✈️ Midnight eVTOL cleared Phase 3 FAA cert, plus a defense partnership with Anduril on Thunder VTOL. $1.7B+ cash on hand. Our model: ~$10.75/share, ~102% upside. Not financial advice.
$ACHR
#stocks
PLTR is up 14% today, here's why.
Palantir crushed Q2: revenue $1.94B vs $1.8B expected, EPS $0.41 vs $0.35 est. US commercial revenue grew 149% YoY.
Not financial advice. $PLTR